A Phase 1/2 open label study of Nivolumab monotherapy or Nivolumab combined with Ipilimumab in subjects with advanced or metastatic solid tumors.
Clinical Trial Grant
Awarded By
Bristol-Myers Squibb Company
Start Date
April 1, 2014
End Date
October 28, 2024
Awarded By
Bristol-Myers Squibb Company
Start Date
April 1, 2014
End Date
October 28, 2024